Owners, management and financials
CVR: 10888638
Secondary names: BROCADES PHARMA A/S, ASTELLAS A/S, YAMANOUCHI PHARMA A/S
Previous names: A/S PSE 13 NR. 1079, GIST-BROCADES PHARMACEUTICALS A/S, BROCADES PHARMA A/S
EUR 197,863,000
Revenue
Net result: EUR 5,229,000
Astellas Pharma Europe LTD. (100%)
CVR · view owners
Mark Andree Dekker
Board: Damla Ebru Atilgan (chair) and 3 members
CVR · view management
Active
Founded 1 July 1987
CVR · view overview
80 employees
CVR · 2018
Director role ended: Morten Auscher
CVR · 01/12/2025
View the full event history
ASTELLAS PHARMA A/S is a Danish company of the type Aktieselskab based in København S, founded in 1987. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named YAMANOUCHI PHARMA A/S and BROCADES PHARMA A/S. The management consists of Mark Andree Dekker. The board consists of Damla Ebru Atilgan (chair), Anne Nymand, Giuseppe Maduri and Mark Andree Dekker. The company is owned by Astellas Pharma Europe LTD.. The company has 80 employees (2018). In 2026, the company reported revenue of EUR 197,863,000 and a net result of EUR 5,229,000 compared with EUR 5,705,000 the year before. Equity in the 2026 report amounted to EUR 20,071,000.
Source: annual report 2026, Danish Business Authority
Astellas Pharma A/S shows a stable financial trajectory with a slight increase in revenue, reaching €197.9 million in 2026, up from €179.9 million in 2022. However, profitability has fluctuated, with profit declining from €6.7 million in 2022 to €5.2 million in 2026, indicating potential concerns regarding margin management. The company's equity has decreased significantly from €58.2 million in 2022 to €20.1 million in 2026, raising questions about its long-term financial stability. Positioned within the pharmaceutical wholesale industry, Astellas Pharma A/S must address these equity and profitability challenges to maintain its competitive edge.
AI-generated summary · Generated 13/08/2026
Selskabets formål er: at etablere, at erhverve og at finansiere, at deltage i og udføre management i andre virksomheder, at handle med produkter indenfor fødevare-, sundheds- og miljøområdet, at udvikle og/eller at producere sådanne produkter, alt i videste forstand, at erhverve og afhænde immaterialrettigheder og at udøve enhver handling, som er knyttet til eller er en konsekvens af det foranstående i videst muligt omfang.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202601/04/2025 – 31/03/2026 | 197.9 mio. EUR | 5.2 mio. EUR | 111 mio. EUR | 20.1 mio. EUR | 0 | |
| 202501/04/2024 – 31/03/2025 | 191 mio. EUR | 5.7 mio. EUR | 110 mio. EUR | 20.8 mio. EUR | 96 | |
| 202401/04/2023 – 31/03/2024 | 186.9 mio. EUR | 4.5 mio. EUR | 100.8 mio. EUR | 24.7 mio. EUR | 97 | |
| 202301/04/2022 – 31/03/2023 | 180.8 mio. EUR | 2.1 mio. EUR | 112 mio. EUR | 35.3 mio. EUR | 120 | |
| 202201/04/2021 – 31/03/2022 | 179.9 mio. EUR | 6.7 mio. EUR | 345.6 mio. EUR | 58.2 mio. EUR | 120 | |
| 202101/04/2020 – 31/03/2021 | 160.5 mio. EUR | 5.9 mio. EUR | 145.5 mio. EUR | 59.4 mio. EUR | 115 | |
| 202001/04/2019 – 31/03/2020 | 187 mio. EUR | 2 mio. EUR | 127 mio. EUR | 53.6 mio. EUR | 114 | |
| 201901/04/2018 – 31/03/2019 | 182.6 mio. EUR | 4.7 mio. EUR | 129.6 mio. EUR | 56.2 mio. EUR | 116 | |
| 201801/04/2017 – 31/03/2018 | 157.8 mio. EUR | 2.6 mio. EUR | 103.2 mio. EUR | 54.1 mio. EUR | 115 | |
| 201701/04/2016 – 31/03/2017 | 144.9 mio. EUR | 12.2 mio. EUR | 82.2 mio. EUR | 51.5 mio. EUR | 117 | |
| 201601/04/2015 – 31/03/2016 | 156 mio. EUR | 6.7 mio. EUR | 85.5 mio. EUR | 45.4 mio. EUR | 118 | |
| 201501/04/2014 – 31/03/2015 | 121.9 mio. EUR | 5.3 mio. EUR | 79.6 mio. EUR | 38.7 mio. EUR | 116 | |
| 201401/04/2013 – 31/03/2014 | 97 mio. EUR | 7 mio. EUR | 50.4 mio. EUR | 38.4 mio. EUR | 112 | |
| 201301/04/2012 – 31/03/2013 | 93 mio. EUR | 5.7 mio. EUR | 44.7 mio. EUR | 34.4 mio. EUR | 90 |
Compared to 405 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
7 public tenders won
Sources: TED (the EU tender database) and udbud.dk
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationThe CVR number of ASTELLAS PHARMA A/S is 10888638.
ASTELLAS PHARMA A/S is owned by Astellas Pharma Europe LTD..
The management of ASTELLAS PHARMA A/S consists of Mark Andree Dekker.
The board of ASTELLAS PHARMA A/S consists of Damla Ebru Atilgan, Anne Nymand and Giuseppe Maduri, with Damla Ebru Atilgan as chair.
In 2026, ASTELLAS PHARMA A/S reported revenue of EUR 197,863,000.
ASTELLAS PHARMA A/S had 80 employees in 2018 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
ASTELLAS PHARMA A/S has published its annual report for 2026. Revenue came to DKK 197,863,000, and the net result was DKK 5,229,000.
Contact info changed: new phone: 43430355 (June 2, 2026).
As of June 1, 2026, Anne Nymand has joined the board of directors of ASTELLAS PHARMA A/S.
As of June 1, 2026, Giuseppe Maduri has joined the board of directors of ASTELLAS PHARMA A/S.
As of May 31, 2026, Malene Abildstrøm has left the board of directors of ASTELLAS PHARMA A/S.
As of May 31, 2026, Rowena Borenstein has left the board of directors of ASTELLAS PHARMA A/S.
ASTELLAS PHARMA A/S has won the tender "Amgros 2026 1.472.a" issued by Amgros I/S worth 34,700,000 DKK.
ASTELLAS PHARMA A/S has won the tender "Amgros 2026 1.450.b" issued by Amgros I/S worth 72,960,000 DKK.
ASTELLAS PHARMA A/S has won the tender "Amgros 2026 1.580.a" issued by Amgros I/S worth 165,000,000 DKK.
As of December 1, 2025, Mark Andree Dekker has joined the board of directors of ASTELLAS PHARMA A/S.
As of December 1, 2025, Morten Auscher has left the board of directors of ASTELLAS PHARMA A/S.
As of December 1, 2025, Mark Andree Dekker is registered as director of ASTELLAS PHARMA A/S.
As of December 1, 2025, Morten Auscher has stepped down as adm. dir. of ASTELLAS PHARMA A/S.
ASTELLAS PHARMA A/S has published its annual report for 2025. Revenue came to DKK 191,027,000, and the net result was DKK 5,705,000.
As of March 11, 2025, Morten Auscher has joined the board of directors of ASTELLAS PHARMA A/S.
As of March 11, 2025, Karl Håkan Lennart Widen has left the board of directors of ASTELLAS PHARMA A/S.
As of March 11, 2025, Morten Auscher is registered as adm. dir. of ASTELLAS PHARMA A/S.
As of March 11, 2025, Karl Håkan Lennart Widen has stepped down as adm. dir. of ASTELLAS PHARMA A/S.
ASTELLAS PHARMA A/S has won the tender "Amgros 2025 1.957.b" issued by Amgros I/S worth 434,400,000 DKK.
ASTELLAS PHARMA A/S has won the tender "Amgros 2025 1.1162.a" issued by Amgros I/S worth 1,689,600,000 DKK.
ASTELLAS PHARMA A/S has won the tender "Amgros 2025 1.980.a" issued by Amgros I/S worth 48,000,000 DKK.
ASTELLAS PHARMA A/S has published its annual report for 2024. Revenue came to DKK 186,855,000, and the net result was DKK 4,470,000.
ASTELLAS PHARMA A/S has won the tender "Amgros 2024 1.150.a" issued by Amgros I/S worth 73,756,763 DKK.
ASTELLAS PHARMA A/S has published its annual report for 2023. Revenue came to DKK 180,837,000, and the net result was DKK 2,081,000.
ASTELLAS PHARMA A/S has published its annual report for 2022. Revenue came to DKK 179,933,000, and the net result was DKK 6,689,000.
As of October 6, 2022, Damla Ebru Atilgan has joined the board of directors of ASTELLAS PHARMA A/S.
As of October 6, 2022, Yagnaram Santharam has left the board of directors of ASTELLAS PHARMA A/S.
As of December 14, 2021, Rowena Borenstein has joined the board of directors of ASTELLAS PHARMA A/S.
As of December 14, 2021, Niels Walther-Rasmussen has left the board of directors of ASTELLAS PHARMA A/S.
ASTELLAS PHARMA A/S has published its annual report for 2021. Revenue came to DKK 160,457,000, and the net result was DKK 5,865,000.
As of July 1, 2021, Malene Abildstrøm has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 1, 2021, Karl Håkan Lennart Widen has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 1, 2021, Pia Terésa Lindkvist has left the board of directors of ASTELLAS PHARMA A/S.
As of June 7, 2021, Karl Håkan Lennart Widen is registered as adm. dir. of ASTELLAS PHARMA A/S.
As of June 7, 2021, Pia Terésa Lindkvist has stepped down as adm. dir. of ASTELLAS PHARMA A/S.
ASTELLAS PHARMA A/S has published its annual report for 2020. Revenue came to DKK 187,005,000, and the net result was DKK 2,036,000.
As of June 30, 2020, Yagnaram Santharam has joined the board of directors of ASTELLAS PHARMA A/S.
As of June 30, 2020, Pedro Møllebro has left the board of directors of ASTELLAS PHARMA A/S.
ASTELLAS PHARMA A/S has published its annual report for 2019. Revenue came to DKK 182,590,000, and the net result was DKK 4,735,000.
As of April 1, 2019, Pia Terésa Lindkvist has joined the board of directors of ASTELLAS PHARMA A/S.
As of April 1, 2019, Jan Anders Martin Nordén has left the board of directors of ASTELLAS PHARMA A/S.
As of April 1, 2019, Pia Terésa Lindkvist is registered as adm. dir. of ASTELLAS PHARMA A/S.
As of April 1, 2019, Jan Anders Martin Nordén has stepped down as adm. dir. of ASTELLAS PHARMA A/S.
ASTELLAS PHARMA A/S has published its annual report for 2018. Revenue came to DKK 157,806,000, and the net result was DKK 2,562,000.
ASTELLAS PHARMA A/S has published its annual report for 2017. Revenue came to DKK 144,927,000, and the net result was DKK 12,189,000.
ASTELLAS PHARMA A/S has published its annual report for 2016. Revenue came to DKK 155,987,000, and the net result was DKK 6,656,000.
As of July 6, 2016, Niels Walther-Rasmussen has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 6, 2016, Pedro Møllebro has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 6, 2016, Jan Anders Martin Nordén has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 6, 2016, Nicolaas Jacobus Stander has left the board of directors of ASTELLAS PHARMA A/S.
As of July 6, 2016, Gillian Kay Mitchell has left the board of directors of ASTELLAS PHARMA A/S.
As of July 6, 2016, Mats Stefan Persson has left the board of directors of ASTELLAS PHARMA A/S.
As of July 6, 2016, Jan Anders Martin Nordén is registered as adm. dir. of ASTELLAS PHARMA A/S.
As of July 6, 2016, Mats Stefan Persson has stepped down as adm. dir. of ASTELLAS PHARMA A/S.
As of July 5, 2016, Pedro Møllebro has left the board of directors of ASTELLAS PHARMA A/S.
ASTELLAS PHARMA A/S has published its annual report for 2015. Revenue came to DKK 121,936,000, and the net result was DKK 5,258,000.
As of February 10, 2015, is registered as an owner of ASTELLAS PHARMA A/S with an ownership share of 100%.
As of October 10, 2014, EY Godkendt Revisionspartnerselskab has been appointed auditor of ASTELLAS PHARMA A/S.
As of October 10, 2014, JUT NR. 2180 A/S has stepped down as auditor of ASTELLAS PHARMA A/S.
ASTELLAS PHARMA A/S has published its annual report for 2014. Revenue came to DKK 97,029,000, and the net result was DKK 6,989,000.
ASTELLAS PHARMA A/S has published its annual report for 2013. Revenue came to DKK 92,965,000, and the net result was DKK 5,714,000.
As of August 18, 2011, JUT NR. 2180 A/S has been appointed auditor of ASTELLAS PHARMA A/S.
As of August 18, 2011, EY Danmark A/S has stepped down as auditor of ASTELLAS PHARMA A/S.
As of March 17, 2010, Nicolaas Jacobus Stander has joined the board of directors of ASTELLAS PHARMA A/S.
As of March 17, 2010, Seiji Kinoshita has left the board of directors of ASTELLAS PHARMA A/S.
As of July 12, 2007, Seiji Kinoshita has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 12, 2007, Hiroshi Nogawa has left the board of directors of ASTELLAS PHARMA A/S.
As of August 24, 2005, Gillian Kay Mitchell has joined the board of directors of ASTELLAS PHARMA A/S.
As of August 24, 2005, Hiroshi Nogawa has joined the board of directors of ASTELLAS PHARMA A/S.
As of August 24, 2005, Mats Stefan Persson has joined the board of directors of ASTELLAS PHARMA A/S.
As of August 24, 2005, Herman Levinus Pierre Breepoel has left the board of directors of ASTELLAS PHARMA A/S.
As of August 24, 2005, Wilhelmus Jacques Josephus Kockelkoren has left the board of directors of ASTELLAS PHARMA A/S.
On August 19, 2005, the company changed its name from YAMANOUCHI PHARMA A/S to ASTELLAS PHARMA A/S.
As of May 9, 2005, Mats Stefan Persson is registered as adm. dir. of ASTELLAS PHARMA A/S.
As of May 9, 2005, Herman Levinus Pierre Breepoel has stepped down as director of ASTELLAS PHARMA A/S.
As of March 29, 2004, Herman Levinus Pierre Breepoel has joined the board of directors of ASTELLAS PHARMA A/S.
As of March 29, 2004, Stead Arthur Ellis has left the board of directors of ASTELLAS PHARMA A/S.
As of March 29, 2004, Yasuo Ishii has left the board of directors of ASTELLAS PHARMA A/S.
As of March 29, 2004, Herman Levinus Pierre Breepoel is registered as director of ASTELLAS PHARMA A/S.
As of March 29, 2004, Stead Arthur Ellis has stepped down as director of ASTELLAS PHARMA A/S.
As of December 27, 2002, Johannes Adrianus de Heus has left the board of directors of ASTELLAS PHARMA A/S.
As of December 13, 2002, Pedro Møllebro has joined the board of directors of ASTELLAS PHARMA A/S.
As of December 13, 2002, Wilhelmus Jacques Josephus Kockelkoren has joined the board of directors of ASTELLAS PHARMA A/S.
As of September 30, 2001, Philippe Andre Pierre Ballero has left the board of directors of ASTELLAS PHARMA A/S.
As of February 9, 2001, Yasuo Ishii has joined the board of directors of ASTELLAS PHARMA A/S.
As of February 9, 2001, Shigekazu Takahashi has left the board of directors of ASTELLAS PHARMA A/S.
As of August 30, 2000, Johannes Adrianus de Heus has joined the board of directors of ASTELLAS PHARMA A/S.
As of December 29, 1999, Douwe Wybe Witteveen has left the board of directors of ASTELLAS PHARMA A/S.
As of August 10, 1998, EY Danmark A/S has been appointed auditor of ASTELLAS PHARMA A/S.
As of August 10, 1998, CJ Partnership I/S has stepped down as auditor of ASTELLAS PHARMA A/S.
As of August 10, 1998, Douwe Wybe Witteveen has joined the board of directors of ASTELLAS PHARMA A/S.
As of August 10, 1998, Henricus Johannes Huiberts has left the board of directors of ASTELLAS PHARMA A/S.
As of March 1, 1998, Philippe Andre Pierre Ballero has joined the board of directors of ASTELLAS PHARMA A/S.
As of March 1, 1998, Arend Paasman has left the board of directors of ASTELLAS PHARMA A/S.
As of September 13, 1996, CJ Partnership I/S has stepped down as auditor of ASTELLAS PHARMA A/S.
As of March 3, 1994, Masakatsu Inoue has left the board of directors of ASTELLAS PHARMA A/S.
On February 26, 1994, the company changed its name from BROCADES PHARMA A/S to YAMANOUCHI PHARMA A/S.
On August 21, 1991, the company changed its name from GIST-BROCADES PHARMACEUTICALS A/S to BROCADES PHARMA A/S.
As of June 28, 1991, Berend Nico Huisman has left the board of directors of ASTELLAS PHARMA A/S.
As of June 28, 1991, Berend Nico Huisman has stepped down as director of ASTELLAS PHARMA A/S.
As of March 20, 1991, EY Danmark A/S has stepped down as auditor of ASTELLAS PHARMA A/S.
As of March 20, 1991, Andre Louis De Haas has left the board of directors of ASTELLAS PHARMA A/S.
As of March 20, 1991, Simon Johannes Quist has left the board of directors of ASTELLAS PHARMA A/S.
As of October 18, 1990, has stepped down as auditor of ASTELLAS PHARMA A/S.
As of September 19, 1989, Arnold Johan Westerveld has left the board of directors of ASTELLAS PHARMA A/S.
On January 16, 1988, the company changed its name from A/S PSE 13 NR. 1079 to GIST-BROCADES PHARMACEUTICALS A/S.
As of January 15, 1988, Erik Tronborg Andersen has stepped down as auditor of ASTELLAS PHARMA A/S.
As of January 15, 1988, Ulf Svejgaard Poulsen has left the board of directors of ASTELLAS PHARMA A/S.
As of January 15, 1988, Susanne Saul Stakemann has left the board of directors of ASTELLAS PHARMA A/S.
As of January 15, 1988, Per Emil Hasselbalch Stakemann has left the board of directors of ASTELLAS PHARMA A/S.
As of January 15, 1988, Per Emil Hasselbalch Stakemann has stepped down as director of ASTELLAS PHARMA A/S.
As of July 1, 1987, Erik Tronborg Andersen has been appointed auditor of ASTELLAS PHARMA A/S.
As of July 1, 1987, EY Danmark A/S has been appointed auditor of ASTELLAS PHARMA A/S.
As of July 1, 1987, CJ Partnership I/S has been appointed auditor of ASTELLAS PHARMA A/S.
As of July 1, 1987, CJ Partnership I/S has been appointed auditor of ASTELLAS PHARMA A/S.
As of July 1, 1987, has been appointed auditor of ASTELLAS PHARMA A/S.
As of July 1, 1987, Ulf Svejgaard Poulsen has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 1, 1987, Susanne Saul Stakemann has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 1, 1987, Per Emil Hasselbalch Stakemann has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 1, 1987, Berend Nico Huisman has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 1, 1987, Stead Arthur Ellis has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 1, 1987, Arnold Johan Westerveld has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 1, 1987, Andre Louis De Haas has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 1, 1987, Simon Johannes Quist has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 1, 1987, Arend Paasman has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 1, 1987, Masakatsu Inoue has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 1, 1987, Shigekazu Takahashi has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 1, 1987, Henricus Johannes Huiberts has joined the board of directors of ASTELLAS PHARMA A/S.
As of July 1, 1987, Per Emil Hasselbalch Stakemann is registered as director of ASTELLAS PHARMA A/S.
As of July 1, 1987, Berend Nico Huisman is registered as director of ASTELLAS PHARMA A/S.
As of July 1, 1987, Stead Arthur Ellis is registered as director of ASTELLAS PHARMA A/S.
ASTELLAS PHARMA A/S was founded on July 1, 1987.
Companies in the same industry and area
CVR 39371049
CVR 39503778
CVR 40873309
CVR 31774284
CVR 37285145
